Literature DB >> 16938866

A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR.

Rene L Galindo1, Jay A Allport, Eric N Olson.   

Abstract

Alveolar rhabdomyosarcoma (ARMS) is an aggressive myogenic-type tumor and a gain-of-function disease, caused by misexpression of the PAX3-FKHR or PAX7-FKHR fusion oncoprotein from structurally rearranged chromosomes. PAX3-FKHR misexpressed in terminally differentiating mouse myofibers can cause rhabdomyosarcoma at a low frequency, suggesting that skeletal muscle is an ARMS tissue of origin. Because patterned muscle is widely viewed as irreversibly syncytial, questions persist, however, regarding this potential pathogenetic mechanism for ARMS tumor initiation. To further explore this issue, we generated transgenic Drosophila lines that conditionally express human PAX-FKHR. Here we show that PAX7-FKHR causes nucleated cells to form and separate from syncytial myofibers, which then spread to nonmuscular tissue compartments, including the central nervous system, and that wild-type PAX3 demonstrates similar potential. We further show that Ras, which is known to interfere with the differentiation of myogenic cells, genetically interacts with PAX7-FKHR: constitutively activated Ras enhances PAX7-FKHR phenotypes, whereas loss-of-function ras alleles dominantly suppress PAX7-FKHR activity, including rescue of lethality. These results show that PAX-FKHR can drive the generation of discrete nucleated cells from differentiated myofibers in vivo, argue for syncytial muscle as an ARMS tissue of origin, and demonstrate that Drosophila provides a powerful system to screen for genetic modifiers of PAX-FKHR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938866      PMCID: PMC1569182          DOI: 10.1073/pnas.0605926103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Ras pathway specificity is determined by the integration of multiple signal-activated and tissue-restricted transcription factors.

Authors:  M S Halfon; A Carmena; S Gisselbrecht; C M Sackerson; F Jiménez; M K Baylies; A M Michelson
Journal:  Cell       Date:  2000-09-29       Impact factor: 41.582

2.  Dedifferentiation of mammalian myotubes induced by msx1.

Authors:  S J Odelberg; A Kollhoff; M T Keating
Journal:  Cell       Date:  2000-12-22       Impact factor: 41.582

3.  Myoseverin, a microtubule-binding molecule with novel cellular effects.

Authors:  G R Rosania; Y T Chang; O Perez; D Sutherlin; H Dong; D J Lockhart; P G Schultz
Journal:  Nat Biotechnol       Date:  2000-03       Impact factor: 54.908

4.  Pax3 functions at a nodal point in melanocyte stem cell differentiation.

Authors:  Deborah Lang; Min Min Lu; Li Huang; Kurt A Engleka; Maozhen Zhang; Emily Y Chu; Shari Lipner; Arthur Skoultchi; Sarah E Millar; Jonathan A Epstein
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

5.  The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation.

Authors:  E N Olson; G Spizz; M A Tainsky
Journal:  Mol Cell Biol       Date:  1987-06       Impact factor: 4.272

6.  Genetic transformation of Drosophila with transposable element vectors.

Authors:  G M Rubin; A C Spradling
Journal:  Science       Date:  1982-10-22       Impact factor: 47.728

7.  Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3.

Authors:  M J Anderson; G D Shelton; W K Cavenee; K C Arden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 8.  Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.

Authors:  F G Barr
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

9.  Multiple protein functions of paired in Drosophila development and their conservation in the Gooseberry and Pax3 homologs.

Authors:  L Xue; X Li; M Noll
Journal:  Development       Date:  2001-02       Impact factor: 6.868

10.  The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo.

Authors:  Frédéric Relaix; Mariarosa Polimeni; Didier Rocancourt; Carola Ponzetto; Beat W Schäfer; Margaret Buckingham
Journal:  Genes Dev       Date:  2003-12-01       Impact factor: 11.361

View more
  22 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

Review 2.  Insights into pediatric rhabdomyosarcoma research: Challenges and goals.

Authors:  Marielle E Yohe; Christine M Heske; Elizabeth Stewart; Peter C Adamson; Nabil Ahmed; Cristina R Antonescu; Eleanor Chen; Natalie Collins; Alan Ehrlich; Rene L Galindo; Berkley E Gryder; Heidi Hahn; Sharon Hammond; Mark E Hatley; Douglas S Hawkins; Madeline N Hayes; Andrea Hayes-Jordan; Lee J Helman; Simone Hettmer; Myron S Ignatius; Charles Keller; Javed Khan; David G Kirsch; Corinne M Linardic; Philip J Lupo; Rossella Rota; Jack F Shern; Janet Shipley; Sivasish Sindiri; Stephen J Tapscott; Christopher R Vakoc; Leonard H Wexler; David M Langenau
Journal:  Pediatr Blood Cancer       Date:  2019-06-21       Impact factor: 3.167

3.  Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.

Authors:  Lisa E S Crose; Kathleen A Galindo; Julie Grondin Kephart; Candy Chen; Julien Fitamant; Nabeel Bardeesy; Rex C Bentley; Rene L Galindo; Jen-Tsan Ashley Chi; Corinne M Linardic
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

4.  Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma.

Authors:  Zhongqiu Xie; Mihaela Babiceanu; Shailesh Kumar; Yuemeng Jia; Fujun Qin; Frederic G Barr; Hui Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

5.  Drosophila and mammalian models uncover a role for the myoblast fusion gene TANC1 in rhabdomyosarcoma.

Authors:  Usha Avirneni-Vadlamudi; Kathleen A Galindo; Tiana R Endicott; Vera Paulson; Scott Cameron; Rene L Galindo
Journal:  J Clin Invest       Date:  2011-12-19       Impact factor: 14.808

Review 6.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

Review 7.  Childhood rhabdomyosarcoma: recent advances and prospective views.

Authors:  C Wang
Journal:  J Dent Res       Date:  2011-09-13       Impact factor: 6.116

Review 8.  Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics.

Authors:  Cayetano Gonzalez
Journal:  Nat Rev Cancer       Date:  2013-02-07       Impact factor: 60.716

9.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

10.  A mouse model of rhabdomyosarcoma originating from the adipocyte lineage.

Authors:  Mark E Hatley; Wei Tang; Matthew R Garcia; David Finkelstein; Douglas P Millay; Ning Liu; Jonathan Graff; Rene L Galindo; Eric N Olson
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.